Rajeev Vibhakar
Overview
Explore the profile of Rajeev Vibhakar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
3846
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wang D, Ritz C, Pierce A, Brunt B, Luo Y, Dahl N, et al.
bioRxiv
. 2024 Apr;
PMID: 38559100
MYC-driven medulloblastoma (MB) is a highly aggressive cancer type with poor prognosis and limited treatment options. Through CRISPR-Cas9 screening across MB cell lines, we identified the Mediator-associated kinase CDK8 as...
12.
Griesinger A, Calzadilla A, Grimaldo E, Donson A, Amani V, Pierce A, et al.
Clin Cancer Res
. 2024 Feb;
30(8):1544-1554.
PMID: 38334950
Purpose: There are no effective treatment strategies for children with highest-risk posterior fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) are present in approximately 25% of newly diagnosed PFA...
13.
DeSisto J, Donson A, Griesinger A, Fu R, Riemondy K, Mulcahy Levy J, et al.
Neuro Oncol
. 2023 Nov;
26(3):538-552.
PMID: 37934854
Background: Pediatric high-grade gliomas (PHGG) are aggressive brain tumors with 5-year survival rates ranging from <2% to 20% depending upon subtype. PHGG presents differently from patient to patient and is...
14.
Wolin A, Vincent M, Hotz T, Purdy S, Rosenbaum S, Hughes C, et al.
Neuro Oncol
. 2023 Jul;
25(12):2287-2301.
PMID: 37486991
Background: Medulloblastoma is the most common pediatric brain malignancy. Patients with the Group 3 subtype of medulloblastoma (MB) often exhibit MYC amplification and/or overexpression and have the poorest prognosis. While...
15.
Knox A, Van Court B, Oweida A, Barsh E, DeSisto J, Flannery P, et al.
Front Oncol
. 2023 May;
13:1105395.
PMID: 37124531
Background: Diffuse midline glioma (DMG) is an aggressive pediatric central nervous system tumor with strong metastatic potential. As localized treatment of the primary tumor improves, metastatic disease is becoming a...
16.
Shishido K, Purvis I, Velpula K, Venkataraman S, Vibhakar R, Asuthkar S
Oncol Rep
. 2023 Apr;
49(6).
PMID: 37114557
The most aggressive subtype of medulloblastoma (MB), Group 3, is characterized by MYC amplifications. However, targeting MYC has proven unsuccessful, and there remains a lack of therapeutic targets for treating...
17.
Alimova I, Murdock G, Pierce A, Wang D, Madhavan K, Brunt B, et al.
Neurooncol Adv
. 2023 Mar;
5(1):vdad010.
PMID: 36915612
Background: Atypical teratoid rhabdoid tumors (ATRT) are highly aggressive pediatric brain tumors. The available treatments rely on toxic chemotherapy and radiotherapy, which themselves can cause poor outcomes in young patients....
18.
Walker F, Sobral L, Danis E, Sanford B, Balakrishnan I, Wang D, et al.
bioRxiv
. 2023 Feb;
PMID: 36747867
Dynamic regulation of gene expression is fundamental for cellular adaptation to exogenous stressors. PTEFb-mediated pause-release of RNA polymerase II (Pol II) is a conserved regulatory mechanism for synchronous transcriptional induction...
19.
Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blumel L, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36639156
Background: While major advances have been made in improving the quality of life and survival of children with most forms of medulloblastoma (MB), those with MYC-driven tumors (Grp3-MB) still suffer...
20.
Hendrikse L, Haldipur P, Saulnier O, Millman J, Sjoboen A, Erickson A, et al.
Nature
. 2022 Nov;
612(7940):E12.
PMID: 36446943
No abstract available.